{'fraction_non_alphanumeric': 0.043563068920676205, 'fraction_numerical': 0.027308192457737322, 'mean_word_length': 5.633620689655173, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
LIPOSOMAL DOXORUBICIN AND VINORELBINE COMBINATION IN ADVANCED HEAVILY PRETREATED EPITHELIAL OVARIAN CANCER: A PHASE II AND PHARMACOCINETIC STUDY

ovarian malignancy, at diagnosis, after surgery, during first line chemotherapy, follow up and disease recurrence. We retrospectively reviewed the charts of patients with epithelial ovarian cancer who were diagnosed, treated and followed up at San Matteo Hospital of Pavia from 1990 to 2001. Data were collected regarding age, body mass index, previous deep vein thrombosis and pulmonary embolism, menopause status, stage, grade, histology, type of surgery, residual disease, first line chemotherapy and relapse status. All deep vein thrombosis and pulmonary embolism were diagnosed on the basis of clinical symptoms and confirmed by ultrasound, gasometric data, electrocardiography, chest X ray and spiral computer tomography. A total of 253 cases were identified. The overall incidence of clinical thromboembolic events was 16,6% (42 patients), 1,6% (4) of pulmonary embolism and 15% (38) of vein thrombosis. Events at diagnosis were 8 (3,2%), in the postoperative period 6 (2,4%), during first line chemotherapy 15 (5,9%) and throughout follow up 13 (5,1%), of these 5 (2%) with recurrent disease and 8 (3,2%) during chemotherapy. Prognostic factors were evaluated by univariate and multivariate analysis. The incidence of venous thromboembolic events throughout the entire history: of ovarian malignancy is high. Prognostic factors could be used to evaluate prophylaxis in defined period.